Definitive Radiotherapy in Locally Advanced Non-Small Cell Lung Cancer: Dose and Fractionation

被引：4
作者：
Dagoglu, Nergiz [1 ]
Karaman, Sule [2 ]
Arifoglu, Alptekin [3 ]
Kucucuk, Seden [1 ]
Oral, Ethem N. [1 ]
机构：
[1] Istanbul Univ, Istanbul Fac Med, Dept Radiat Oncol, Istanbul, Turkey
[2] Liv Hosp, Dept Radiat Oncol, Istanbul, Turkey
[3] Neolife Med Ctr, Dept Radiat Oncol, Istanbul, Turkey
来源：
BALKAN MEDICAL JOURNAL | 2014年 / 31卷 / 04期
关键词：
Dose; fractionation; non-small cell lung cancer; radiotherapy; THERAPY-ONCOLOGY-GROUP; HYPERFRACTIONATED ACCELERATED RADIOTHERAPY; 3-DIMENSIONAL CONFORMAL RADIOTHERAPY; PHASE-III TRIAL; RANDOMIZED MULTICENTER TRIAL; RADIATION-THERAPY; CONCURRENT CHEMOTHERAPY; INDUCTION CHEMOTHERAPY; CONVENTIONAL RADIOTHERAPY; I/II TRIAL;
D O I：
10.5152/balkanmedj.2014.14496
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Definitive radiotherapy plays a major role in the treatment of locally advanced non-small cell lung cancer (LA NSCLC). After the impact of RT dose for lung cancer was established, a number of trials were structured with the aim of better local control and overall survival by either dose escalation or shortening the total treatment time through conventional/altered fractionation, even in combination with chemotherapy (CT) and other targeted agents. In spite of the increased number of these studies, the optimal dose or fractionation still remains to be determined. Another aspect questioned is the incorporation of these higher doses and shorter treatment times with chemotherapy or targeted agents. This review summarises the results of significant trials on dose and altered fractionation in the treatment of LA-NSCLC with an emphasis on possible future perspectives.
引用
收藏
页码：278 / 285
页数：8
相关论文
共 36 条
  • [1] Final results of the randomized phase III CHARTWEL-trial (ARO 97-1) comparing hyperfractionated-accelerated versus conventionally fractionated radiotherapy in non-small cell lung cancer (NSCLC)
    Baumann, M.
    Herrmann, T.
    Koch, R.
    Matthiessen, W.
    Appold, S.
    Wahlers, B.
    Kepka, L.
    Marschke, G.
    Feltl, D.
    Fietkau, R.
    Budach, V.
    Dunst, J.
    Dziadziuszko, R.
    Krause, M.
    Zips, D.
    [J]. RADIOTHERAPY AND ONCOLOGY, 2011, 100 (01) : 76 - 85
  • [2] Phase III study of the eastern cooperative oncology group (ECOG 2597): Induction chemotherapy followed by either standard thoracic radiotherapy or hyperfractionated accelerated radiotherapy for patients with unresectable stage IIIA and B non-small-cell lung cancer
    Belani, CP
    Wang, W
    Johnson, DH
    Wagner, H
    Schiller, J
    Veeder, M
    Mehta, M
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 3760 - 3767
  • [3] Final results of a Phase I/II dose escalation trial in non-small-cell lung cancer using three-dimensional conformal radiotherapy
    Belderbos, Jose S. A.
    Heemsbergen, Wilma D.
    De Jaeger, Katrien
    Baas, Paul
    Lebesque, Joos V.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2006, 66 (01): : 126 - 134
  • [4] Toxicity and outcome results of RTOG 9311: A phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma
    Bradley, J
    Graham, MV
    Winter, K
    Purdy, JA
    Komaki, R
    Roa, WH
    Ryu, JK
    Bosch, W
    Emami, B
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2005, 61 (02): : 318 - 328
  • [5] Bradley J, 2011, 53 ANN M AM SOC RAD
  • [6] A PHASE I/II RADIATION DOSE ESCALATION STUDY WITH CONCURRENT CHEMOTHERAPY FOR PATIENTS WITH INOPERABLE STAGES I TO III NON-SMALL-CELL LUNG CANCER: PHASE I RESULTS OF RTOG 0117
    Bradley, Jeffrey D.
    Moughan, Jennifer
    Graham, Mary V.
    Byhardt, Roger
    Govindan, Ramaswamy
    Fowler, Jack
    Purdy, James A.
    Michalski, Jeff M.
    Gore, Elizabeth
    Choy, Hak
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010, 77 (02): : 367 - 372
  • [7] Toxicity Report of a Phase 1/2 Dose-Escalation Study in Patients With Inoperable, Locally Advanced Nonsmall Cell Lung Cancer With Helical Tomotherapy and Concurrent Chemotherapy
    Bral, Samuel
    Duchateau, Michael
    Versmessen, Harijati
    Verdries, Douwe
    Engels, Benedikt
    De Ridder, Mark
    Tournel, Koen
    Collen, Christine
    Everaert, Hendrik
    Schallier, Denis
    De Greve, Jacques
    Storme, Guy
    [J]. CANCER, 2010, 116 (01) : 241 - 250
  • [8] Individualized hypo/hyperfractionated radiotherapy for non-small cell lung cancer
    Chang, Joe Y.
    De Ruysscher, Dirk
    [J]. JOURNAL OF THORACIC DISEASE, 2014, 6 (04) : 285 - 286
  • [9] A RANDOMIZED PHASE-I/II TRIAL OF HYPERFRACTIONATED RADIATION-THERAPY WITH TOTAL DOSES OF 60.0 GY TO 79.2 GY - POSSIBLE SURVIVAL BENEFIT WITH GREATER-THAN-OR-EQUAL-TO 69.6 GY IN FAVORABLE PATIENTS WITH RADIATION-THERAPY ONCOLOGY GROUP STAGE-III NON-SMALL-CELL LUNG-CARCINOMA - REPORT OF RADIATION-THERAPY ONCOLOGY GROUP 83-11
    COX, JD
    AZARNIA, N
    BYHARDT, RW
    SHIN, KH
    EMAMI, B
    PAJAK, TF
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (09) : 1543 - 1555
  • [10] Sequential vs Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer: Randomized Phase III Trial RTOG 9410
    Curran, Walter J., Jr.
    Paulus, Rebecca
    Langer, Corey J.
    Komaki, Ritsuko
    Lee, Jin S.
    Hauser, Stephen
    Movsas, Benjamin
    Wasserman, Todd
    Rosenthal, Seth A.
    Gore, Elizabeth
    Machtay, Mitchell
    Sause, William
    Cox, James D.
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2011, 103 (19) : 1452 - 1460
1234